Exchange: NASDAQ·Updated 06:27 AM EDT
News
all
press releases
Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit
10x Genomics won a $4.8 million patent infringement lawsuit against Qiagen subsidiary Parse Biosciences, prompting plans for an injunction.read more...
Benzinga
More News
TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences
10x Genomics wins a $4.8M patent verdict against Parse, strengthening its IP position as it seeks added damages and a U.S. injunction.
Zacks
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences 10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences PR Newswire PLEASANTON, Calif., Aug. 28, 2026 Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity...
PR Newswire
SLS, IBRX Eye Fresh Oncology Tailwind As Cathie Wood’s ARK Backs Personalized Cancer-Vaccine Future
ARK sees a path toward custom cancer treatments for every patient, though current costs of $200,000-$300,000 remain a major hurdle.
Stocktwits
TXG August 2027 Options Begin Trading
Investors in 10x Genomics Inc (Symbol: TXG) saw new options begin trading today, for the August 2027 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 361 days until expiration the newly trading contrac...
Nasdaq News: Markets
10x Genomics (TXG) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Cathie Wood Bought The NVDA Dip Across Five Funds – Here’s What Else ARK Bought And Sold
ARKK and ARKG completely exited their respective positions in 10x Genomics.
Stocktwits
10x Genomics Q2 Earnings & Revenues Beat Estimates, Gross Margin Up
TXG beats Q2 earnings and revenue estimates, expands gross margin and raises its 2026 revenue outlook despite a year-over-year sales decline.
Zacks
10x Genomics (TXG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates
10x Genomics (TXG) delivered earnings and revenue surprises of +39.13% and +2.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.